Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study.
Journal
Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
01
05
2021
revised:
19
06
2021
accepted:
01
11
2021
pubmed:
17
11
2021
medline:
5
4
2022
entrez:
16
11
2021
Statut:
ppublish
Résumé
Data from germline testing in unselected patients with hepatobiliary cancers are limited. Identification of germline predisposition can have important implications on cancer treatment and family counseling. To determine prevalence of pathogenic germline variants (PGV) in patients with hepatobiliary cancer, we undertook a prospective multi-site study of germline sequencing using a >80-gene next-generation sequencing platform among patients with hepatobiliary cancers receiving care at Mayo Clinic Cancer Centers between April 1, 2018 and March 31, 2020. Patients were not selected on the basis of stage, family cancer history, ethnicity, or age. Family cascade testing was offered at no cost. Of 205 patients, the median age was 65 years, 58.5% were male, 81% were White, and 64.4% had cholangiocarcinoma, 21.5% hepatocellular carcinoma, 7.8% gallbladder cancer, and 4.3% carcinoma of ampulla of Vater. PGV were found in 15.6% (
Identifiants
pubmed: 34782326
pii: 1940-6207.CAPR-21-0189
doi: 10.1158/1940-6207.CAPR-21-0189
pmc: PMC9662853
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
121-128Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
Gastroenterology. 2018 Dec;155(6):1828-1837.e2
pubmed: 30144434
J Natl Cancer Inst. 2019 Jan 1;111(1):95-98
pubmed: 30239769
PLoS One. 2014 Sep 16;9(9):e107177
pubmed: 25225801
J Natl Cancer Inst. 2018 Oct 1;110(10):1067-1074
pubmed: 29506128
Gynecol Oncol. 2020 Jan;156(1):140-146
pubmed: 31780235
Gastroenterology. 2015 Oct;149(5):1226-1239.e4
pubmed: 26099527
J Clin Oncol. 2017 Jul 10;35(20):2232-2239
pubmed: 28402748
JAMA Oncol. 2021 Feb 01;7(2):230-237
pubmed: 33126242
Cancer. 2020 Jan 1;126(9):1995-2002
pubmed: 32012241
J Hepatol. 2019 Jul;71(1):104-114
pubmed: 30910538
Oncologist. 2016 May;21(5):594-9
pubmed: 27000463
Cancer. 2019 May 1;125(9):1441-1448
pubmed: 30620386
Chin Clin Oncol. 2020 Feb;9(1):6
pubmed: 32075397
Hepatology. 2015 Oct;62(4):1190-200
pubmed: 26146815
Genet Test Mol Biomarkers. 2013 May;17(5):367-75
pubmed: 23448386
Clin Gastroenterol Hepatol. 2008 Mar;6(3):333-8
pubmed: 18258490
J Natl Compr Canc Netw. 2019 Apr 1;17(4):302-310
pubmed: 30959462
Oncologist. 2017 Jul;22(7):804-810
pubmed: 28487467
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
JAMA Oncol. 2017 Mar 01;3(3):391-397
pubmed: 28033448
J Hepatol. 2018 May;68(5):959-969
pubmed: 29360550
Oncotarget. 2019 Oct 15;10(57):5949-5957
pubmed: 31666926
NPJ Genom Med. 2019 Sep 13;4:22
pubmed: 31531230